Overview

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Status:
Unknown status
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Myelodysplastic syndrome (MDS) is a rare, potentially serious bone marrow disease. Currently available treatments for MDS have been only somewhat beneficial. The purpose of this study is to determine the effects of the medication antithymocyte globulin (ATG) in adults with MDS and to determine which individuals with MDS are most likely to benefit from treatment with ATG.
Phase:
Phase 2
Details
Lead Sponsor:
Office of Rare Diseases (ORD)
Collaborator:
Rare Diseases Clinical Research Network
Treatments:
Antilymphocyte Serum
Prednisone